Updates in the Use of Targeted Therapies for Gynecologic Cancers

鈥� An ASCO Reading Room selection

August 7, 2024

Evelyn Cantillo, MD, MPH, Felix Blanc-Durand, MD, Alexandra Leary, MD, PhD, Brian M. Slomovitz, MD, Katherine Fuh, MD, PhD, and Christina Washington, MD

ASCO Educational Book

This Reading Room is a collaboration between 麻豆传媒庐 and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Targeted therapies have changed the treatment landscape in gynecologic cancer. Studies released over the past year have led to the incorporation of immunotherapy (IO) into the treatment for all patients with endometrial and cervical cancers at some point during their disease course.

Poly(ADP-ribose) polymerase (PARP) inhibitors continue to play a role in women with ovarian carcinoma, particularly in homologous repair deficient tumors. Furthermore, the benefit of PARP inhibitors in challenging subgroups continues to be elucidated.

Biomarker identification has led to the approval or compendium listing of several antibody-drug conjugates (ADCs). This review will update on IO, ADCs, and PARP inhibition for the treatment of gynecologic cancers.

Read an interview about the review here.

Read the full article

Updates in the Use of Targeted Therapies for Gynecologic Cancers

Primary Source

ASCO Educational Book

Source Reference:

麻豆传媒